B. Riley Issues Positive Outlook for RadNet Earnings

Key Points

• B. Riley has raised their earnings per share estimate for RadNet's Q3 2025 to $0.19, indicating confidence in the company's financial performance.
• RadNet reported Q2 earnings of $0.31 per share, exceeding expectations, with revenue increasing 8.4% year-over-year to $498.23 million.
• The stock currently holds an average rating of "Buy" and has a target price of $69.60, reflecting a favorable outlook from multiple analysts.

RadNet, Inc. (NASDAQ:RDNT - Free Report) - B. Riley boosted their Q3 2025 earnings per share (EPS) estimates for RadNet in a note issued to investors on Tuesday, August 12th. B. Riley analyst Y. Zhi now forecasts that the medical research company will post earnings of $0.19 per share for the quarter, up from their prior forecast of $0.18. B. Riley has a "Strong-Buy" rating on the stock. The consensus estimate for RadNet's current full-year earnings is $0.56 per share. B. Riley also issued estimates for RadNet's Q4 2025 earnings at $0.23 EPS.

RadNet (NASDAQ:RDNT - Get Free Report) last released its earnings results on Sunday, August 10th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.17 by $0.14. The firm had revenue of $498.23 million for the quarter, compared to analysts' expectations of $488.06 million. RadNet had a positive return on equity of 2.41% and a negative net margin of 0.78%. The business's revenue for the quarter was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.16 earnings per share.

Several other equities analysts also recently commented on the company. Morgan Stanley upgraded RadNet to an "overweight" rating in a research report on Monday. Wall Street Zen downgraded RadNet from a "hold" rating to a "sell" rating in a research report on Sunday, June 29th. Truist Financial set a $74.00 target price on RadNet in a research report on Thursday, July 10th. Finally, Raymond James Financial reiterated a "strong-buy" rating and issued a $75.00 target price (up from $66.00) on shares of RadNet in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $71.60.

RadNet Trading Up 0.5%

RadNet stock traded up $0.34 during trading hours on Wednesday, hitting $68.75. The stock had a trading volume of 1,052,383 shares, compared to its average volume of 994,313. The company has a quick ratio of 2.01, a current ratio of 2.00 and a debt-to-equity ratio of 0.91. The stock has a market cap of $5.29 billion, a price-to-earnings ratio of -343.73 and a beta of 1.43. RadNet has a one year low of $45.00 and a one year high of $93.65. The business's 50 day simple moving average is $57.20 and its 200-day simple moving average is $55.95.

Institutional Investors Weigh In On RadNet

A number of hedge funds have recently added to or reduced their stakes in the business. Beck Mack & Oliver LLC increased its holdings in RadNet by 6.9% in the first quarter. Beck Mack & Oliver LLC now owns 3,280,449 shares of the medical research company's stock worth $163,104,000 after purchasing an additional 211,570 shares in the last quarter. RTW Investments LP increased its holdings in RadNet by 9.4% in the fourth quarter. RTW Investments LP now owns 1,978,582 shares of the medical research company's stock worth $138,184,000 after purchasing an additional 169,978 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in RadNet by 6.6% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,801,559 shares of the medical research company's stock worth $100,203,000 after purchasing an additional 112,284 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in RadNet by 81.4% in the first quarter. T. Rowe Price Investment Management Inc. now owns 1,657,613 shares of the medical research company's stock worth $82,417,000 after purchasing an additional 743,922 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in RadNet by 2.3% in the second quarter. Geode Capital Management LLC now owns 1,640,188 shares of the medical research company's stock worth $93,354,000 after purchasing an additional 37,403 shares in the last quarter. 77.90% of the stock is currently owned by institutional investors.

Insider Buying and Selling at RadNet

In other news, EVP Alma Gregory Sorensen sold 55,000 shares of the business's stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $56.48, for a total value of $3,106,400.00. Following the transaction, the executive vice president directly owned 1,160,509 shares of the company's stock, valued at $65,545,548.32. The trade was a 4.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 5.60% of the company's stock.

About RadNet

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.